NYMC Faculty Publications
Two-year Outcomes of Bioresorbable Vascular Scaffold Versus Drug-Eluting Stents in Coronary Artery Disease: A Meta-analysis
DOI
10.1136/heartjnl-2016-310886
Journal Title
Heart
First Page
1096
Last Page
1103
Document Type
Article
Publication Date
7-1-2017
Department
Medicine
Abstract
BACKGROUND: Data regarding long-term clinical outcomes with everolimus-eluting bioresorbable vascular scaffold (BVS) versus second-generation drug-eluting stents (DES) are scarce.
METHODS: We searched online databases until October 2016 for studies comparing BVS versus DES reporting outcomes at 2 years of follow-up. We performed a meta-analysis comparing BVS with DES across the spectrum of coronary artery disease (CAD). Random effects model OR was calculated for outcomes of interest including device-oriented composite events (DOCE; defined as composite of cardiac mortality, target vessel myocardial infarction (TV-MI), and ischaemia-driven target lesion revascularisation (TLR)), all-cause mortality, definite stent thrombosis, TV-MI and TLR.
RESULTS: A total of 2360 patients enrolled in five studies met criteria for inclusion in this analysis. At 2 years, BVS was associated with higher rates of DOCE (6.9% vs 4.5%, OR=1.53; 95% CI 1.06 to 2.23; p=0.02), absolute risk increase (ARI) 2.4%, relative risk increase (RRI) 53%, TV-MI (4% vs 1.8%, OR=1.94; 95% CI 1.02 to 3.67; p=0.04), ARI 2.2%, RRI 122% and definite stent thrombosis (2.1% vs 0.6%, OR=3.39; 95% CI 1.46 to 7.88; p=0.005), ARI 1.5%, RRI 250% compared with DES. No differences in all-cause mortality (OR=0.86; 95% CI 0.26 to 2.81; p=0.80) and TLR (OR=1.44; 95% CI 0.81 to 2.54; p=0.21) were observed between both groups.
CONCLUSIONS: BVS may be associated with worse long-term clinical outcomes compared with DES. Randomised clinical trials are encouraged to expeditiously report long-term safety and efficacy outcomes and identify predictors of adverse events with BVS compared with DES.
Recommended Citation
Nairooz, R., Saad, M., Sardar, P., & Aronow, W. S. (2017). Two-year Outcomes of Bioresorbable Vascular Scaffold Versus Drug-Eluting Stents in Coronary Artery Disease: A Meta-analysis. Heart, 103 (14), 1096-1103. https://doi.org/10.1136/heartjnl-2016-310886
Publisher's Statement
Originally published in Heart. The original material can be found here.